Part II of this Note will review the statutory purpose of the Lanham Act and discuss the application of trade dress protection under the Act. Part III will consider the Third Circuit's construction of trade dress law in the SK&F decision. Finally, Part IV of this Note will address the questions raised by the holding in Shire US, Inc. v Barr Laboratories, Inc., namely: (1) whether prescription drug trade dress should be analyzed under traditional notions of trade dress law, and if not, (2) whether the Lanham Act is the appropriate vehicle for protecting a prescription drug tablet's trade dress, or (3) in the alternative, whether prescription drug tablets should be analyzed under a modified trade dress framework. Such an alternative will be proposed.
II. The Lanham Act and Trade Dress Protection
The Lanham Act was intended to make "actionable the deceptive and misleading use of marks" and to "protect persons engaged in . . . commerce against unfair competition." 11 A trademark under the Act is defined as "any word, name, symbol, or device or any combination thereof . . . [used] to identify and distinguish . . . goods, including a unique product, from those manufactured or sold by others and to indicate the source of the goods . . . ." 12 The Lanham Act does not require that the specific source of the product be identifiable from the trademark; rather, the trademark must simply enable a consumer to identify that the product came from a single source.
13
In addition to protecting registered trademarks, § 43(a) of the Lanham Act creates a federal cause of action for trade dress infringement. 14 The Supreme Court has interpreted the language of this section broadly, expanding the realm of protectable trade dress to anything 11 Lanham Act § 45, 15 U.S.C. § 1127 (1999) . 12 Id. 13 See id. 14 15 U.S.C. § 1125(a); Wal-Mart Stores, Inc. v. Samara Bros., 529 U.S. 205, 209 (2000) .
"human beings might use as a 'symbol' or 'device' . . . that is capable of carrying meaning." 15 Therefore, trade dress "involves the total image of a product and may include features such as size, shape, color or color combinations, texture, graphics, or even particular sales techniques." 16 As the Court set out in Wal-Mart Stores, Inc. v. Samara Bros., for a product's trade dress to fall within the purview of the Lanham Act's protections, the producer must show: (1) that the trade dress is either inherently distinctive, or is said to be distinctive as a result of acquiring "secondary meaning;" (2) that there is a likelihood of consumer confusion; and (3) that the alleged infringing feature is nonfunctional. Generic and descriptive marks cannot gain trademark protections because they merely refer to "the genus of which a particular product is a species." 19 Generally, they are the common names of products that convey "an immediate idea of the ingredients, qualities or characteristics of the goods." 20 Courts recognize an exception to this general rule, allowing merely descriptive marks to gain distinctiveness by acquiring secondary meaning. 21 "To establish secondary meaning, a manufacturer must show that, in the minds of the public, the primary significance of a product feature or term is to identify the source of the product rather than the product itself. secure to the owner of the mark the goodwill of his business and to protect the ability of the consumers to distinguish among competing producers. National protection of trademarks is desirable . . . because trademarks foster competition and the maintenance of quality by securing to the producer the benefits of good reputation.
33
If it were more difficult to gain protection on inherently distinctive trade dress, competition between producers would be hindered because copycats could enter the market under the same trade dress, thereby nullifying the Lanham Act's policies of ensuring quality and fostering competition. Therefore, to comport with Congress' intent, the Supreme Court construed § 43(a)'s distinctiveness element as requiring a an initial inquiry into whether a product is inherently distinctive , allowing for the possibility that a product can receive protection even absent proof of secondary meaning.
B. Likelihood of Consumer Confusion
Because a market economy requires competition to remain functional and healthy, it is permissible and desirable for a new business to produce products similar to ones already in existence. However, the Lanham Act precludes the later-arriving producer from gaining its market share through the use of another manufacturer's trade dress. This restriction is premised on one of the Act's underlying policies -alleviating consumer confusion. 35 Prior to 2000, the Third Circuit analyzed "likelihood of confusion" differently depending upon whether the alleged trade dress infringer was dealing in competing or noncompeting 32 Id. at 774. 33 (1) the degree of similarity between the owner's mark [or trade dress] and the alleged infringing mark;
(2) the strength of the owner's mark;
(3) the price of the goods and other factors indicative of the care and attention expected of consumers when making a purchase;
(4) the length of time the defendant has used the mark without evidence of actual confusion arising;
(5) the intent of the defendant in adopting the mark;
(6) the evidence of actual confusion;
(7) whether the goods, though not competing, are marketed through the same channels of trade and advertised through the same media;
(8) the extent to which the targets of the parties' sales efforts are the same;
(9) the relationship of the goods in the minds of consumers, whether because of the nearidentity of the products, the similarity of function, or other factors; and (10) other facts suggesting that the consuming public might expect the prior owner to manufacture a product in the defendant's market, or that he is likely to expand into that market.
39
In had prescribed the SKF product for 15 years to millions of patients, and that SKF's was the only product in the diuretic market using the maroon and white color scheme.
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On appeal to the Third Circuit, Premo reiterated several arguments in favor of permitting copying SKF's trade dress. First, Premo suggested that making generic products look like brandname counterparts was desirable "to facilitate identification of a particular medication of a particular strength . . . ." 54 Next, Premo argued that the standardization of color, size, and shape is important to both ensure that the proper drug is dispensed and to assist in rapid identification of medications in emergency situations.
55
Premo also predicted that physicians would be confused when trying to visually identify a prescription drug. 56 Finally, Premo suggested that patients feel more confident taking a generic product when its chemical make-up is the same as that of its brand-name counterpart.
57
The appellate court rejected these arguments in short order. As to the assertions regarding identification of drugs, the court relied on testimony of physicians who stated that they would never rely upon trade dress as the sole means of identifying a prescription drug. 58 The court rejected the argument that patients would lose confidence in generic drugs that don't resemble brand-name counterparts because most states require that a patient be informed of a generic substitution. 59 Moreover, the court reasoned that even if standardization of the color scheme for the purpose of easing patient anxiety was a viable argument, Premo's generic drug was not composed of the same amount of each ingredient as SKF's brand-name drug. 60 The 53 Id. at 1059. 54 Id. at 1060. 55 Id. 56 Id. 57 Id. at 1061. 58 Id. at 1060. 59 Id. at 1061. 60 Id.
court determined that while the generic drug may be chemically similar to the brand-name drug, the variation in ingredients could lead to dangerously different reactions in a given patient.
61
The Third Circuit relied on the traditional trade dress infringement analysis. The court gave deference to the trial court's finding that the trade dress was distinctive. 62 In considering the likelihood of confusion, the court found that the products would confuse consumers because the tablets were colored similarly and the logos were so small that they were ineffective. 63 Finally, the court found that the color, shape, and size of the tablet were nonfunctional because
he adoption of that trade dress was arbitrary, having nothing to do with the purpose or performance of the drug, or with its processing." 64 Having found all of the elements for the cause of action to be present, the court affirmed the lower court's determination that Premo infringed SKF's trade dress under § 43(a) of the Lanham Act.
65
In SK&F, the Third Circuit broadly construed the Lanham Act, thereby granting prescription drugs a wide range of protection for the trade dress of their tablets. In addition to the reasons stated herein, the court also likely considered that, unlike over-the-counter drugs, a prescription drug manufacturer relies on its product's trade dress as the only visible, sourceidentifying feature within its control. Accordingly, the court found that prescription drug trade dress deserves heightened protection. and sold its tablets in two colors, a blue 10mg tablet and an orange 20mg tablet, both stamped with an "AD" on one side and the dosage on the other. 67 Shire promoted its product through literature, featuring colored pictures of the drug, which was distributed to physicians. 68 Barr Laboratories, Inc. ("Barr"), began selling a generic version of Adderall in 2002. 69 It adopted a color scheme very similar to Shire's, in which lower dosage tablets were blue and higher dosage tablets were orange. Both were stamped with a "b" on one side and a serial number on the other. 70 The trial court found that Shire's Adderall and Barr's generic product were of the same coloring and were "similar but not identical." 71 Further, the court considered Shire's assertion that the ingredients of the generic substitute were not identical: Barr's generic drug contained the inactive ingredient saccharin, a once controversial substance.
IV
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In denying Shire's request for preliminary injunction, the Third Circuit attempted to distinguish its 1980 SK&F decision from the facts presented in Shire. Ultimately, all of the methods employed by the court to do so failed. First, the court asserted that the evidence in SK&F indicated that actual "passing off" had occurred within pharmacies. 73 However, the SK&F court construed New Jersey common law, not the Lanham Act, in making its finding of passing off. 74 Moreover, the court did not find that actual passing off had occurred in the earlier case, but rather that it could "reasonably anticipate" that passing off may occur. 75 Thus, the Shire court that passing off was a distinguishing factor was unpersuasive, as the court certainly could have "reasonably anticipated" that pharmacies may pass off the similarly colored tablets present in Shire.
Next, the court attempted to justify its departure from precedent by finding that the tablet's trade dress in Shire was functional, while the SK&F court considered a non-functional product features. 76 In so doing, the court considered, but failed to give sufficient weight to, the fact that the functionality arguments raised in Shire were very similar to those in SK&F. In
Shire, the evidence of functionality relied on by the court consisted of affidavits from physicians stating that generic manufacturers should be permitted to use similar color schemes to those of brand name tablets because color coding would lead to: (1) less patient confusion, (2) proper patient adjustment from one medicinal strength to another, (3) proper dosing for children whose medications are administered by non-medical personnel, and (4) increased acceptance and comfort for patients using generic medication. 77 Although these assertions seem logical, they are the very arguments that the Third Circuit rejected as evidence of functionality in SK&F.
78
Instead of establishing a bright line rule for whether color, size, and shape of prescription tablets are functional elements of trade dress, the court merely deferred to the trial court's finding of premise that trade dress protection is over-extended, an unconsidered question remains: Should prescription pharmaceutical tablets seeking trade dress protection be subjected to the same analyses as traditional product design goods?
V. Prescription Pharmaceutical Tablets and Traditional Trade Dress Protection
As discussed above, Wal-Mart instructs the circuit courts to constrict the trade dress protection afforded to product design goods. 89 The Supreme Court was primarily concerned with the effect that granting trade dress protection to designs of such products would have on competition. 90 In determining that product design should never be inherently distinctive, the Court cited both the deterrent effect of a "plausible threat of [a] successful suit" involving an allegedly inherent design on hindrances to competition, and its finding that design could not likely inherently identify the source of a good. 91 Furthermore, the Court reasoned that any inherently distinctive design could certainly obtain a design patent or be protected by copyright laws.
92
Likely underlying the court's assertions was the knowledge that manufacturers of such products also had the ability to create source-identifying product packaging. 93 Regrettably, the court's premise fails when applied to the discreet class of prescription drug tablets. The 88 Shire, 329 F.3d at 358. 89 For an example of a court affording trade dress protection to a traditional product design due to its inherent distinctiveness, see Ashley Furniture Indus., Inc. v. Sangiacomo N. A., Ltd., 187 F.3d 363 (4 th Cir. 1999) (protecting bedroom furniture). 90 Wal-Mart, 529 U.S. at 213. 91 Id. at 214. 92 Id. 93 For example, furniture may be shipped in boxes that carry the name and logo of its manufacturer, thereby identifying the source of the product. See Ashley Furniture Indus., Inc., 187 F.3d at 363. producers of these products do not have the same source-identifying product packaging available to them as do other types of products. The tablets are packaged in bottles capped with white lids.
White labels on the side of the container indicate patient information, dosage, the prescribing doctor, and the type of drug. These labels are provided by the pharmacist; the manufacturer has no control over the aesthetics of the labels. Thus, the tablet design itself is the only real sourceidentifying characteristic available to the manufacturer. To take advantage of the protections granted to inherently distinctive trade dress, drug producers have accordingly developed unique color schemes, shapes, and sizes for their tablets.
Under Shire, these unique tablet designs have lost any protection they may have possessed under trade dress law, absent a showing of secondary meaning. While restricting trade dress protection of prescription drug tablets may seem to be justified in light of the large profits drug manufacturers amass through available patent protections, it will likely prove to be an inefficient means of curtailing a drug manufacturer's protections. Restriction could have a widespread and adverse financial impact on an already overpriced pharmaceutical market. Shire and Wal-Mart effectively hold that the only way pharmaceutical companies can acquire trade dress protection for prescription drug tablets is to gain distinctiveness through secondary meaning. Secondary meaning is primarily gained through expending millions of dollars on advertising in various media so that consumers will recognize the manufacturer as the source of the drug. 94 Unintended though the result may be, pharmaceutical companies will be forced to increase their advertising budgets to obtain any degree of assurance of protection.
It is reasonable to assume that at least a portion of any increase in the cost of production will in turn be assigned to the consuming public. That the consumer class cannot afford to pay these continually rising and unnecessary advertising costs was made evident by recent events in Springfield, Massachusetts. In order to take advantage of reduced cross-border prices, the city government struck a deal with Canadian drug producers whereby the city agreed to purchase its prescription drugs from the Canadian producers instead of American companies. 95 This action not only eased the cost of health care but also relieved the city's significant deficit. 96 The border crossing of prescription drugs will continue to occur, as consumers will seek alternative sources of medication until the prices of prescription drugs in the United States are reduced. Eliminating the requirement that drug manufacturers saturate the media with advertisements would be an obvious step toward easing prices.
Significant financial cuts could also be achieved by granting protections to drug producers who direct their advertisements to medical practitioners, instead of consumers.
Historically, prescription drugs were only advertised to the drug prescribers, since they alone decided which drugs were prescribed. 97 As patients became more active in their own health care, represented the single largest increase in spending on consumer-directed advertising. 101 It cannot merely be coincidence that Wal-Mart was decided during this same period. Under the case's reasoning, pharmaceutical companies must increase product awareness among the consuming public before they can gain trade dress protection. To accomplish this goal, manufacturers are forced to increase their budgets for consumer-directed advertising. This phenomenon can only result in heightened spending on consumer-directed advertising in order to receive trade dress protection. In turn, the consuming public will pay higher and higher prices for prescription drugs. To the extent that manufacturers are influenced by this unintended effect of the Shire and
Wal-Mart holdings, removing the effective prerequisite of increased advertising would lessen the financial burden on both manufacturers and, indirectly, on consumers.
VI. The Possible Resolution
To resolve the potential problems created by Shire, the Third Circuit might follow one of two approaches. First, the court could eliminate trade dress protection for pharmaceuticals entirely. This action would alleviate the burden on manufacturers to extensively advertise while still satisfying the court's desire to restrict trade dress protections. By completely removing prescription drug tablets from the realm of trade dress protection, pharmaceutical manufacturers would be less inclined to advertise to consumers, since secondary meaning would no longer be a path to distinctiveness. This approach would also allow generic manufacturers to use brandname trade dress without fear of prosecution under the Lanham Act, which was the Supreme of the Shire and Wal-Mart courts, it is unlikely that the Third Circuit would take such a drastic step.
More plausibly, the court could entirely exclude prescription drugs from traditional trade dress analysis and create a new approach specifically tailored for the idiosyncrasies of the prescription drug industry. As discussed above, traditional trade dress analysis assumes product packaging by which the manufacturer can be identified as the source of the good. Prescription drugs lack such packaging. To account for these major discrepancies, the court should establish new criteria for determining whether a prescription drug tablet's trade dress has been infringed.
A. Distinctiveness
Distinctiveness should no longer be considered when determining trade dress infringement for prescription drug tablets. Under the patent system, most pharmaceuticals companies have a twenty-year period in which they are allowed monopolistic control over their drugs. 103 As a result, the majority of the consuming public will recognize a drug by its color, shape and size of the tablet. Even if this recognition would fail to qualify as secondary meaning under the traditional trade analysis, it would be sufficient to establish distinctiveness under this proposed analysis. Accordingly, the need for pharmaceutical companies to expend excess money on advertising to gain secondary meaning, as is required under the traditional system, would be eliminated. The resulting reduction in spending would help to ease the financial tension that currently burdens the pharmaceutical market. Shire regarding the functionality of a tablet's trade dress do not fall within either of these definitions espoused in TrafFix. The Shire court reasoned that no protection should be afforded to the tablet's trade dress because a patient may be more comfortable taking a drug that uses the brand-name trade dress. However, the trade dress adopted for Shire's tablet was chosen arbitrarily; it had nothing to do with the purpose or performance of the drug, or with its processing.
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This is the type of reputation-based disadvantage that trade dress law was designed to protect.
C. Likelihood of Consumer Confusion
The final element, likelihood of confusion, would become the central and defining element under the new approach. However, the traditional Lapp factors would have to be slightly modified to accommodate the unique concerns present in a prescription drug trade dress analysis:
1.
The Similarity of the Prescription Drug Tablets
This factor would remain relatively intact from the traditional analysis. Courts would have to compare the allegedly infringing tablet with the brand-name tablet to determine the degree of similarity between them. However, they would apply a new standard, inquiring whether a reasonable consumer of a particular medication could differentiate between the brandname drug tablet and the allegedly infringing generic drug tablet. A negative finding would be a strong indication that the generic manufacturer has infringed the brand-name manufacturer's trade dress. This factor would serve to encourage generic drug producers to choose distinct appearances for their products, thereby minimizing consumer confusion. Furthermore, disallowing identical tablets would lessen the threat of passing off or capsule switching, because consumers would be better able to distinguish between various types of pills.
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If trade dresses are similar but not identical then the following subfactors should also be considered:
a. Bioavailability
The bioavailability of a drug is the quantity of active ingredients that are released into the bloodstream per unit dosage. 108 Under the proposed analysis, courts would look to laboratory analyses to determine whether the bioavailability of the brand-name drug tablet and the generic drug tablet are identical. The importance of bioavailability cannot be understated because a consumer may not realize that a substitution has been made if the trade dress of two types of medication is very similar. A patient's health could be seriously at risk if two pills appear alike but have different bioavailability. No consumer should be subjected to such serious confusion and potential harm when taking prescription medication. Accordingly, under the new framework, if a court was to find that the bioavailability of a brand-name tablet and a generic product were the same, it would hold that the generic tablet does not confuse consumers.
Although the significance of a drug's bioavailability has been greatly reduced by the FDA's current regulations of generic drugs, it should certainly continue to be considered when determining the likelihood of consumer confusion.
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b.
Availability of Inactive Ingredients
In Shire, the Court recognized, but failed to give adequate weight to, the fact that Barr's generic drug contained the inactive ingredient saccharin. 110 Until recently, saccharin was banned by the FDA as a suspected carcinogen. 111 Many people would still prefer to avoid ingesting the substance, regardless of its FDA classification. For this reason, this factor retains its significance. Thus, a court should take into account the list of inactive ingredients when determining whether a tablet's trade dress is infringing. If the lists of inactive ingredients were found to be identical or equivalent, then the tablet's trade dress would not confuse consumers.
2.
Intent of the Generic Drug Manufacturer
Courts should also consider the intent of the generic drug manufacturer in adopting the similar or identical trade dress. As mentioned above, passing off, or capsule switching, is one of the reoccurring problems that the courts encounter in the pharmaceutical industry. 112 If a court was to find that a generic drug manufacturer purposefully copied a brand-name trade dress for the purpose of passing off or intentionally confusing consumers in any way, then such a finding would strongly indicate a likelihood of confusion.
State Law Regarding Disclosure of Generic Substitutions
Most states permitting generic substitutions require that purchasers be notified when a brand-name drug has been substituted by a generic equivalent.
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Notification under the proposed approach would require a consumer to sign a document explaining that such a substitution of a brand-name drug has been made. Pharmacists would be charged with the duty of explaining the document to consumers. As a result of this requirement, generic drugs that look similar to their brand-name counterparts would be less likely to cause confusion among consumers. A properly executed notification would indicate to a court that there was no likelihood of confusion in a given case.
VII. Conclusion
Today, brand-name prescription drug manufacturers are unable to protect good will and product recognition. These competitive advantages, which are gained only through years' worth of investment, can be quickly wiped out if a generic drug manufacturer decides to imitate a brand-name product. The Third Circuit's opinion in Shire has dealt yet another blow to this already weak area of protection. As a result of that decision, brand-name prescription drug companies will be required to spend even more money in advertising and marketing to regain the protection that was once afforded to them under SK&F. The manufacturers' increased operating costs will ultimately be passed along to consumers of prescription drugs, as is evidenced by
United States citizens purchasing their prescription medication in Canada at lower prices.
Weakening prescription drug trade dress will only further complicate these interrelated problems.
Although the changes to prescription drug trade dress law proposed in this Note do not cure these
